News | November 06, 2024
Pfizer reports Q3 2024 revenue higher by 32% at US$ 17.7 billion
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Subscribe To Our Newsletter & Stay Updated
